Skip to main content
Top
Published in: Familial Cancer 3/2012

01-09-2012 | Original Article

Cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital based Lynch syndrome registry

Authors: Mala Pande, Chongjuan Wei, Jinyun Chen, Christopher I. Amos, Patrick M. Lynch, Karen H. Lu, Laura A. Lucio, Stephanie G. Boyd-Rogers, Sarah A. Bannon, Maureen E. Mork, Marsha L. Frazier

Published in: Familial Cancer | Issue 3/2012

Login to get access

Abstract

The spectrum of cancers seen in a hospital based Lynch syndrome registry of mismatch repair gene mutation carriers was examined to determine the distribution of cancers and examine excess cancer risk. Overall there were 504 cancers recorded in 368 mutation carriers from 176 families. These included 236 (46.8 %) colorectal and 268 (53.2 %) extracolonic cancers. MLH1 mutation carriers had a higher frequency of colorectal cancers whereas MSH2, MSH6 and PMS2 mutation carriers had more extracolonic cancers although these differences were not statistically significant. Men had fewer extracolonic cancers than colorectal (45.3 vs. 54.7 %), whereas women had more extracolonic than colorectal cancers (59.0 vs. 41.0 %). The mean age at diagnosis overall for extracolonic cancers was older than for colorectal, 49.1 versus 44.8 years (P ≤ 0.001). As expected, the index cancer was colorectal in 58.1 % of patients and among the extracolonic index cancers, endometrial was the most common (13.8 %). A significant number of non-Lynch syndrome index cancers were recorded including breast (n = 5) prostate (n = 3), thyroid (n = 3), cervix (n = 3), melanoma (n = 3), and 1 case each of thymoma, sinus cavity, and adenocarcinoma of the lung. However, standardized incidence ratios calculated to assess excess cancer risk showed that only those cancers known to be associated with Lynch syndrome were significant in our sample. We found that Lynch syndrome patients can often present with cancers that are not considered part of Lynch syndrome. This has clinical relevance both for diagnosis of Lynch syndrome and surveillance for cancers of different sites during follow-up of these patients.
Literature
1.
go back to reference Geary J, Sasieni P, Houlston R, Izatt L, Eeles R, Payne SJ, Fisher S, Hodgson SV (2008) Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer 7:163–172PubMedCrossRef Geary J, Sasieni P, Houlston R, Izatt L, Eeles R, Payne SJ, Fisher S, Hodgson SV (2008) Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer 7:163–172PubMedCrossRef
2.
go back to reference Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, Llor X, Xicola RM, Rodriguez-Moranta F, Paya A, Jover R, Bessa X (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293:1986–1994PubMedCrossRef Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, Llor X, Xicola RM, Rodriguez-Moranta F, Paya A, Jover R, Bessa X (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293:1986–1994PubMedCrossRef
3.
go back to reference Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen M, Harkonen N, Julkunen R, Kangas E, Ojala S, Tulikoura J, Valkamo E, Jarvinen H, Mecklin JP, Aaltonen LA, de la Chapelle A (2000) Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 18:2193–2200PubMed Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen M, Harkonen N, Julkunen R, Kangas E, Ojala S, Tulikoura J, Valkamo E, Jarvinen H, Mecklin JP, Aaltonen LA, de la Chapelle A (2000) Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 18:2193–2200PubMed
4.
go back to reference Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Clendenning M, Sotamaa K, Prior T, Westman JA, Panescu J, Fix D, Lockman J, LaJeunesse J, Comeras I, de la Chapelle A (2008) Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26:5783–5788 Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Clendenning M, Sotamaa K, Prior T, Westman JA, Panescu J, Fix D, Lockman J, LaJeunesse J, Comeras I, de la Chapelle A (2008) Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26:5783–5788
5.
go back to reference Lynch HT, Ens J, Lynch JF, Watson P (1988) Tumor variation in three extended Lynch syndrome II kindreds. Am J Gastroenterol 83:741–747PubMed Lynch HT, Ens J, Lynch JF, Watson P (1988) Tumor variation in three extended Lynch syndrome II kindreds. Am J Gastroenterol 83:741–747PubMed
7.
go back to reference Lin KM, Shashidharan M, Ternent CA, Thorson AG, Blatchford GJ, Christensen MA, Lanspa SJ, Lemon SJ, Watson P, Lynch HT (1998) Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population. Dis Colon Rectum 41:428–433PubMedCrossRef Lin KM, Shashidharan M, Ternent CA, Thorson AG, Blatchford GJ, Christensen MA, Lanspa SJ, Lemon SJ, Watson P, Lynch HT (1998) Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population. Dis Colon Rectum 41:428–433PubMedCrossRef
8.
go back to reference da Silva FC, de Oliveira LP, Santos EM, Nakagawa WT, Aguiar JS, Valentin MD, Rossi BM, de Oliveira FF (2010) Frequency of extracolonic tumors in Brazilian families with Lynch syndrome: analysis of a hereditary colorectal cancer institutional registry. Fam Cancer 9:563–570PubMedCrossRef da Silva FC, de Oliveira LP, Santos EM, Nakagawa WT, Aguiar JS, Valentin MD, Rossi BM, de Oliveira FF (2010) Frequency of extracolonic tumors in Brazilian families with Lynch syndrome: analysis of a hereditary colorectal cancer institutional registry. Fam Cancer 9:563–570PubMedCrossRef
10.
go back to reference Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 116:1453–1456PubMedCrossRef Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 116:1453–1456PubMedCrossRef
11.
go back to reference Lynch HT, Fusaro RM, Roberts L, Voorhees GJ, Lynch JF (1985) Muir-Torre syndrome in several members of a family with a variant of the Cancer Family Syndrome. Br J Dermatol 113:295–301PubMedCrossRef Lynch HT, Fusaro RM, Roberts L, Voorhees GJ, Lynch JF (1985) Muir-Torre syndrome in several members of a family with a variant of the Cancer Family Syndrome. Br J Dermatol 113:295–301PubMedCrossRef
12.
go back to reference Schwartz RA, Torre DP (1995) The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol 33:90–104PubMedCrossRef Schwartz RA, Torre DP (1995) The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol 33:90–104PubMedCrossRef
13.
14.
go back to reference Peltomaki P, Vasen HF (1997) Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International collaborative group on hereditary nonpolyposis colorectal cancer. Gastroenterology 113:1146–1158PubMedCrossRef Peltomaki P, Vasen HF (1997) Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International collaborative group on hereditary nonpolyposis colorectal cancer. Gastroenterology 113:1146–1158PubMedCrossRef
15.
go back to reference Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM, Cavalieri RJ, Boland CR (1993) Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 104:1535–1549PubMed Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM, Cavalieri RJ, Boland CR (1993) Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 104:1535–1549PubMed
16.
go back to reference Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, Taal BG, Moller P, Wijnen JT (2001) MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 19:4074–4080PubMed Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, Taal BG, Moller P, Wijnen JT (2001) MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 19:4074–4080PubMed
17.
go back to reference Bai YQ, Akiyama Y, Nagasaki H, Lu SL, Arai T, Morisaki T, Kitamura M, Muto A, Nagashima M, Nomizu T, Iwama T, Itoh H, Baba S, Iwai T, Yuasa Y (1999) Predominant germ-line mutation of the hMSH2 gene in Japanese hereditary non-polyposis colorectal cancer kindreds. Int J Cancer 82:512–515PubMedCrossRef Bai YQ, Akiyama Y, Nagasaki H, Lu SL, Arai T, Morisaki T, Kitamura M, Muto A, Nagashima M, Nomizu T, Iwama T, Itoh H, Baba S, Iwai T, Yuasa Y (1999) Predominant germ-line mutation of the hMSH2 gene in Japanese hereditary non-polyposis colorectal cancer kindreds. Int J Cancer 82:512–515PubMedCrossRef
18.
go back to reference Kim JC, Kim HC, Roh SA, Koo KH, Lee DH, Yu CS, Lee JH, Kim TW, Lee HL, Beck NE, Bodmer WF (2001) hMLH1 and hMSH2 mutations in families with familial clustering of gastric cancer and hereditary non-polyposis colorectal cancer. Cancer Detect Prev 25:503–510PubMed Kim JC, Kim HC, Roh SA, Koo KH, Lee DH, Yu CS, Lee JH, Kim TW, Lee HL, Beck NE, Bodmer WF (2001) hMLH1 and hMSH2 mutations in families with familial clustering of gastric cancer and hereditary non-polyposis colorectal cancer. Cancer Detect Prev 25:503–510PubMed
19.
go back to reference Rossi BM, Lopes A, Oliveira FF, Nakagawa WT, Napoli Ferreira CC, Casali Da Rocha JC, Simpson CC, Simpson AJ (2002) hMLH1 and hMSH2 gene mutation in Brazilian families with suspected hereditary nonpolyposis colorectal cancer. Ann Surg Oncol 9:555–561PubMed Rossi BM, Lopes A, Oliveira FF, Nakagawa WT, Napoli Ferreira CC, Casali Da Rocha JC, Simpson CC, Simpson AJ (2002) hMLH1 and hMSH2 gene mutation in Brazilian families with suspected hereditary nonpolyposis colorectal cancer. Ann Surg Oncol 9:555–561PubMed
20.
go back to reference Liu M, Scheurer ME, Bondy ML, Strom SS, Amos CI, Etzel CJ (2007) Extension of the cohort analysis for genetic epidemiology program to assess excess risk of cancer. American Statistical Association. Proceeding of the 2007 Joint Statistical Meeting, pp 2546–2550 Liu M, Scheurer ME, Bondy ML, Strom SS, Amos CI, Etzel CJ (2007) Extension of the cohort analysis for genetic epidemiology program to assess excess risk of cancer. American Statistical Association. Proceeding of the 2007 Joint Statistical Meeting, pp 2546–2550
21.
go back to reference Bandipalliam P, Garber J, Kolodner RD, Syngal S (2004) Clinical presentation correlates with the type of mismatch repair gene involved in hereditary nonpolyposis colon cancer. Gastroenterology 126:936–937PubMedCrossRef Bandipalliam P, Garber J, Kolodner RD, Syngal S (2004) Clinical presentation correlates with the type of mismatch repair gene involved in hereditary nonpolyposis colon cancer. Gastroenterology 126:936–937PubMedCrossRef
22.
go back to reference Jensen UB, Sunde L, Timshel S, Halvarsson B, Nissen A, Bernstein I, Nilbert M (2010) Mismatch repair defective breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. Breast Cancer Res Treat 120:777–782PubMedCrossRef Jensen UB, Sunde L, Timshel S, Halvarsson B, Nissen A, Bernstein I, Nilbert M (2010) Mismatch repair defective breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. Breast Cancer Res Treat 120:777–782PubMedCrossRef
23.
go back to reference Walsh MD, Buchanan DD, Cummings MC, Pearson SA, Arnold ST, Clendenning M, Walters R, McKeone DM, Spurdle AB, Hopper JL, Jenkins MA, Phillips KD, Suthers GK, George J, Goldblatt J, Muir A, Tucker K, Pelzer E, Gattas MR, Woodall S, Parry S, Macrae FA, Haile RW, Baron JA, Potter JD, Le ML, Bapat B, Thibodeau SN, Lindor NM, McGuckin MA, Young JP (2010) Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry. Clin Cancer Res 16:2214–2224PubMedCrossRef Walsh MD, Buchanan DD, Cummings MC, Pearson SA, Arnold ST, Clendenning M, Walters R, McKeone DM, Spurdle AB, Hopper JL, Jenkins MA, Phillips KD, Suthers GK, George J, Goldblatt J, Muir A, Tucker K, Pelzer E, Gattas MR, Woodall S, Parry S, Macrae FA, Haile RW, Baron JA, Potter JD, Le ML, Bapat B, Thibodeau SN, Lindor NM, McGuckin MA, Young JP (2010) Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry. Clin Cancer Res 16:2214–2224PubMedCrossRef
24.
go back to reference Muller A, Edmonston TB, Corao DA, Rose DG, Palazzo JP, Becker H, Fry RD, Rueschoff J, Fishel R (2002) Exclusion of breast cancer as an integral tumor of hereditary nonpolyposis colorectal cancer. Cancer Res 62:1014–1019 Muller A, Edmonston TB, Corao DA, Rose DG, Palazzo JP, Becker H, Fry RD, Rueschoff J, Fishel R (2002) Exclusion of breast cancer as an integral tumor of hereditary nonpolyposis colorectal cancer. Cancer Res 62:1014–1019
25.
go back to reference de Leeuw WJ, van PM, Tollenaar RA, Cornelisse CJ, Vasen HF, Morreau H (2003) Correspondence re: A. Muller et al., Exclusion of breast cancer as an integral tumor of hereditary nonpolyposis colorectal cancer. Cancer Res 63:1148–1149 de Leeuw WJ, van PM, Tollenaar RA, Cornelisse CJ, Vasen HF, Morreau H (2003) Correspondence re: A. Muller et al., Exclusion of breast cancer as an integral tumor of hereditary nonpolyposis colorectal cancer. Cancer Res 63:1148–1149
26.
go back to reference Vasen HF, Morreau H, Nortier JW (2001) Is breast cancer part of the tumor spectrum of hereditary nonpolyposis colorectal cancer? Am J Hum Genet 68:1533–1535 Vasen HF, Morreau H, Nortier JW (2001) Is breast cancer part of the tumor spectrum of hereditary nonpolyposis colorectal cancer? Am J Hum Genet 68:1533–1535
27.
go back to reference Bauer CM, Ray AM, Halstead-Nussloch BA, Dekker RG, Raymond VM, Gruber SB, Cooney KA (2011) Hereditary prostate cancer as a feature of Lynch syndrome. Fam Cancer 10:37–42 Bauer CM, Ray AM, Halstead-Nussloch BA, Dekker RG, Raymond VM, Gruber SB, Cooney KA (2011) Hereditary prostate cancer as a feature of Lynch syndrome. Fam Cancer 10:37–42
28.
go back to reference Grindedal EM, Moller P, Eeles R, Stormorken AT, Bowitz-Lothe IM, Landro SM, Clark N, Kvale R, Shanley S, Maehle L (2009) Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol Biomarkers Prev 18:2460–2467 Grindedal EM, Moller P, Eeles R, Stormorken AT, Bowitz-Lothe IM, Landro SM, Clark N, Kvale R, Shanley S, Maehle L (2009) Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol Biomarkers Prev 18:2460–2467
Metadata
Title
Cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital based Lynch syndrome registry
Authors
Mala Pande
Chongjuan Wei
Jinyun Chen
Christopher I. Amos
Patrick M. Lynch
Karen H. Lu
Laura A. Lucio
Stephanie G. Boyd-Rogers
Sarah A. Bannon
Maureen E. Mork
Marsha L. Frazier
Publication date
01-09-2012
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2012
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-012-9534-6

Other articles of this Issue 3/2012

Familial Cancer 3/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine